Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
Open Access
- 9 September 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 28 (5) , 309-319
Abstract
Background: Spiromax ® is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes ( in vitro dosing consistency with budesonide–formoterol (DuoResp) Spiromax; flow rates through empty versions of the Spiromax and Turbuhaler inhaler) of importance to patients with asthma or COPD. Methods: Dose-delivery studies were performed using low-, middle-, and high-strength DuoResp Spiromax. Dose consistency was assessed over inhaler life. Total emitted doses (TEDs) were measured at various flow rates, after exposure to high and low temperature or humidity, at different inhaler orientations, and after dropping the inhaler. The criterion for evaluating dose uniformity was whether mean TEDs were within the product specification limits. In separate studies, flow rates were measured after training, using the patient information leaflets, and again after enhanced training as part of a randomized, open-label, cross-over study. Results: Mean values for both budesonide and formoterol were within 85%–115 % of the label claim for each strength of DuoResp Spiromax for initial dose uniformity and for the other investigated conditions (temperature, humidity, orientation, dropping, knocking), with the exception of approximately an 80 % increase in first dose after dropping the inhaler (subsequent doses not affected). In the flow rate patient study, two patients' inhalations with Spiromax and six with Turbuhaler were 60 L/min. Conclusions: DuoResp Spiromax consistently meets dose uniformity criteria, under controlled laboratory conditions and with variations intended to mimic real-world use. Following enhanced training, all patients in the flow study were able to achieve the minimal inspiratory flow rate of >30 L/min, which is required for effective treatment.Keywords
This publication has 19 references indexed in Scilit:
- P227 Efficacy And Safety Of Budesonide-formoterol (bf) Spiromax(R) In Adults And Adolescents With Asthma: Randomised Comparison With Bf Turbuhaler(R)Thorax, 2014
- The Inhalation Characteristics of Patients When They Use Different Dry Powder InhalersJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2014
- Inhaler mishandling remains common in real life and is associated with reduced disease controlRespiratory Medicine, 2011
- What the pulmonary specialist should know about the new inhalation therapiesEuropean Respiratory Journal, 2011
- Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?Respiratory Medicine, 2007
- Are outcomes the same with all dry powder inhalers?International Journal Of Clinical Practice, 2005
- Assessment of Handling of Inhaler Devices in Real Life: An Observational Study in 3811 Patients in Primary CareJournal of Aerosol Medicine, 2003
- Training Issues in the Use of InhalersDisease Management and Health Outcomes, 2001
- Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalersInternational Journal of Pharmaceutics, 1997
- The Relationship Between Powder Inhaler Resistance and Peak Inspiratory Conditions in Healthy Volunteers — Implications for In Vitro TestingJournal of Aerosol Medicine, 1993